LEO Pharma Acquires Dersimelagon for Rare Skin Diseases
BALLERUP, DENMARK, August 18, 2026 LEO Pharma has entered into an agreement to acquire worldwide rights to dersimelagon from...
InnoCare Pharma
Advertisement
Smith+Nephew and Imperial Advance Surgical Robotics
LONDON, August 18, 2026 Smith+Nephew and Imperial College London have launched a new five-year partnership to accelerate innovation in...
InnoCare Advances Phase III AML Trial of Mesutoclax
BEIJING, August 18, 2026 InnoCare Pharma announced that China’s Center for Drug Evaluation (CDE) of the National Medical Products...
InnoCare Secures China Breakthrough Therapy Status for Marginal Zone Lymphoma Therapy
BEIJING, Aug. 4, 2026 InnoCare Pharma announced that the China National Medical Products Administration (NMPA) Center for Drug Evaluation...
Philips Reports Strong Q2 2026 Growth and AI Innovation
Amsterdam, Netherlands, July 27, 2026 Royal Philips has reported solid second-quarter 2026 financial results, driven by 4% comparable sales...
Advertisements
InnoCare Phase III TYK2 Study Meets Psoriasis Endpoint
Beijing, July 27, 2026 InnoCare Pharma has announced that its novel TYK2 (Tyrosine Kinase 2) inhibitor fadeucravacitinib (ICP-488) successfully...
InnoCare Reports Positive Phase II Soficitinib Results
Beijing, July 16, 2026 InnoCare Pharma announced that the Phase II portion of its adaptive Phase II/III clinical trial...
InnoCare Wins China NDA Acceptance for Orelabrutinib in ITP
BEIJING — May 28, 2026 InnoCare Pharma announced that China’s Center for Drug Evaluation (CDE) under the National Medical...
InnoCare Advances Phase III Orelabrutinib Trial for SLE
BEIJING, April 29, 2026 InnoCare Pharma has announced that the first patient has been dosed in the registrational Phase...
Advertisement
